1. Introduction

Blue biotechnology refers to the use of marine and aquatic organisms, biological materials, and genetic resources for scientific, industrial, pharmaceutical, agricultural, and environmental applications. It includes research involving marine microorganisms, algae, sponges, corals, fish, marine enzymes, and genetic materials obtained from oceans and other aquatic environments.

Blue biotechnology intellectual property (IP) disputes arise when competing claims are made over the ownership, patentability, use, commercial exploitation, or disclosure of inventions and biological resources derived from marine life.

These disputes are particularly complex because they involve overlapping legal regimes:

Patent law and biotechnology inventions.

Ownership and access to marine genetic resources.

Biodiversity conservation and benefit-sharing.

Trade secrets and confidential research.

Research collaboration and technology transfer.

Indigenous and coastal community interests.

International maritime law and cross-border commercialization.

For example, a pharmaceutical company may isolate a compound from a marine sponge and develop a cancer treatment. A dispute could arise over whether the compound is patentable, whether the original biological material was lawfully obtained, whether a research institution owns the invention, and whether benefits must be shared with the source country or community.

An important distinction is that a naturally occurring organism or substance is not automatically patentable merely because it has been discovered. Patentability depends on the applicable jurisdiction, the claimed invention, and requirements such as novelty, inventive step, and industrial applicability or utility.

2. Principal categories of disputes

Unlocking marine biotechnology | Research Communities by Springer Nature

A. Patent ownership and patentability

Disputes over marine-derived compounds, enzymes, genetic sequences, extraction techniques, synthetic analogues, and industrial processes. Questions include whether the invention is sufficiently novel and whether a patent claim improperly covers naturally occurring biological material.

Gran Canaria multiplica por cinco los nuevos terrenos para cultivar algas

B. Genetic resources and biopiracy

Conflicts over the collection and commercial use of marine genetic resources without required authorization, mutually agreed terms, or applicable benefit-sharing arrangements.

Establishing a secure connection ...

C. Trade secrets and confidential research

Unauthorized disclosure of experimental results, genomic databases, fermentation methods, unpublished compounds, or proprietary cultivation techniques.

FAU | FAU Marine Science Trailblazer Receives Lifetime Achievement Award

D. Cross-border research and benefit-sharing

Disputes involving research vessels, international laboratories, patent applicants, marine protected areas, and the transfer of biological samples between countries.

3. Legal framework governing blue biotechnology IP disputes

A. Patent law

Patent law generally protects inventions rather than discoveries in the abstract. A marine biotechnology patent application may cover a genuinely inventive process, a modified enzyme, a synthetic compound, a novel composition, or a qualifying genetically engineered organism.

The principal legal questions are:

Novelty: Was the invention already publicly known or disclosed?

Inventive step: Would the invention have been obvious to a skilled person?

Industrial applicability or utility: Can it be used for a recognized practical purpose?

Sufficiency of disclosure: Does the patent specification explain the invention adequately?

Scope of claims: Do the claims extend beyond what the inventor actually developed and disclosed?

Inventorship and ownership: Who conceived the invention, and who legally owns the resulting rights?

The answers vary by jurisdiction. Some legal systems also exclude certain biological material, plant or animal varieties, or inventions contrary to public policy from patent protection.

B. International agreements

1. Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS)

TRIPS establishes minimum standards for patent protection and permits specified exclusions from patentability. Article 27.1 addresses patentability requirements, while Article 27.3(b) addresses certain biological inventions and plant varieties.

2. Convention on Biological Diversity (CBD)

The CBD addresses the conservation of biodiversity, sustainable use, and fair and equitable benefit-sharing arising from the utilization of genetic resources. Its access-and-benefit-sharing framework can be important when marine samples originate within national jurisdiction.

3. Nagoya Protocol

The Nagoya Protocol establishes an international framework for access to genetic resources and benefit-sharing, subject to its scope and the implementing laws of the relevant countries. Its application to particular marine samples depends on factors including jurisdiction, origin, and the legal status of the material.

4. United Nations Convention on the Law of the Sea (UNCLOS)

UNCLOS governs maritime zones, marine scientific research, and aspects of marine-resource rights. National jurisdiction over marine resources differs from the regime for resources in areas beyond national jurisdiction.

5. BBNJ Agreement

The Agreement on the Conservation and Sustainable Use of Marine Biological Diversity of Areas Beyond National Jurisdiction addresses marine genetic resources, including questions of benefit-sharing, in areas beyond national jurisdiction. It entered into force on 17 January 2026. Its rules must be considered alongside other applicable international obligations and domestic implementation.

These instruments serve different functions. Patent ownership does not, by itself, establish that the underlying biological material was lawfully accessed. Conversely, compliance with access and benefit-sharing requirements does not automatically establish that an invention meets patentability standards.

4. Leading case laws and judicial principles

The following cases are relevant to blue biotechnology disputes because they establish principles concerning biological inventions, patent eligibility, genetic-resource rights, and benefit-sharing. Not every case concerns marine organisms directly; several are persuasive analogies rather than blue-biotechnology-specific precedents.

Case 1: Diamond v. Chakrabarty (1980)

United States Supreme Court · 447 U.S. 303 (1980)

Facts: Ananda Chakrabarty developed a genetically engineered bacterium capable of breaking down multiple components of crude oil. He sought patent protection for the engineered organism.

Legal issue: Could a genetically engineered living microorganism qualify as patentable subject matter?

Decision: The US Supreme Court held that the genetically engineered microorganism was patent-eligible under the applicable US statute because it was a human-made invention with distinctive characteristics, rather than merely a naturally occurring organism.

LII / Legal Information Institute

Relevance to blue biotechnology:

A genetically modified marine bacterium designed to degrade oil spills may qualify for patent protection, subject to all applicable requirements.

Engineered marine enzymes or microorganisms may be protectable where the claims define a qualifying invention.

The case does not mean that naturally occurring marine organisms, isolated biological materials, or every genetic discovery are automatically patentable.

Principle: Human ingenuity applied to biological material may produce patent-eligible subject matter, but the precise scope of protection depends on the governing statute and the claimed invention.

Case 2: Association for Molecular Pathology v. Myriad Genetics, Inc. (2013)

United States Supreme Court · 569 U.S. 576 (2013)

Facts: The dispute concerned patents claiming isolated DNA associated with the BRCA1 and BRCA2 genes and synthetically created complementary DNA (cDNA).

Legal issue: Is naturally occurring DNA patentable merely because it has been isolated from its natural environment?

Decision: The Court held that naturally occurring DNA does not become patent-eligible merely through isolation. It distinguished cDNA, which may be patent-eligible because it is not naturally occurring in the same form, subject to applicable limitations.

Relevance to blue biotechnology:

Suppose a laboratory isolates a DNA sequence from a deep-sea microorganism and claims the sequence itself. The fact that the sequence was newly identified does not necessarily establish patent eligibility under US law. A genuinely engineered sequence or a novel application may raise different questions.

Principle: Discovering and isolating a naturally occurring biological feature is legally distinct from creating a qualifying invention.

Case 3: Mayo Collaborative Services v. Prometheus Laboratories, Inc. (2012)

United States Supreme Court · 566 U.S. 66 (2012)

Facts: The patents concerned methods of using relationships between drug-metabolite concentrations and treatment adjustments.

Legal issue: Can a patent monopolize a natural relationship merely by adding conventional steps?

Decision: The Court found the claimed methods patent-ineligible because they effectively claimed natural laws combined with conventional activity insufficient to transform them into patent-eligible applications.

Relevance to blue biotechnology:

A patent claim based on a naturally occurring marine biochemical relationship may face objections if it merely states that relationship and adds routine laboratory procedures. The outcome would depend on the actual claim, its technical contribution, and the jurisdiction's law.

Principle: Patent claims must protect a qualifying application or invention, not improperly monopolize natural phenomena.

Case 4: J.E.M. Ag Supply, Inc. v. Pioneer Hi-Bred International, Inc. (2001)

United States Supreme Court · 534 U.S. 124 (2001)

Facts: The case concerned the patentability of newly developed plant varieties under US utility-patent law.

Decision: The Court upheld the availability of utility patents for qualifying new plant varieties, despite the existence of separate statutory plant-protection regimes.

Relevance to blue biotechnology:

The decision illustrates that specialized statutory protection for biological varieties does not necessarily exclude patent protection for qualifying inventions. However, it concerned plants, not marine organisms, and does not establish a universal rule for marine genetic resources.

Principle: Different forms of biological protection may coexist, depending on the statutory framework and the invention claimed.

Case 5: Monsanto Technology LLC v. Nuziveedu Seeds Ltd. (2019)

Supreme Court of India · (2019) 3 SCC 381

Facts: The dispute involved genetically modified cotton technology, licensing arrangements, and patent protection under Indian law.

Legal issue: How should patent claims involving biological material and biotechnology be assessed in light of the Patents Act, 1970, including exclusions concerning plants and biological processes?

Decision: The Supreme Court set aside the Delhi High Court's decision and remanded the matter for fresh consideration. It did not finally determine all underlying questions of patent validity.

Relevance to blue biotechnology:

A patent involving a genetically modified marine organism must be examined under India's specific patent exclusions, including section 3(j), where relevant.

A licensing dispute can involve both contractual obligations and the statutory limits of patent protection.

A claim cannot be treated as valid simply because the technology is commercially valuable or scientifically advanced.

Principle: Biotechnology patents must be assessed against the precise statutory requirements; the technical description, claim language, and legal exclusions matter.

Case 6: Divya Pharmacy v. Union of India (2018)

Uttarakhand High Court · Writ Petition (M/S) No. 3437 of 2016, decided 21 December 2018

Facts: Divya Pharmacy challenged the regulatory framework requiring benefit-sharing payments in connection with commercial use of biological resources under India's Biological Diversity Act, 2002.

Legal issue: Could Indian entities engaged in commercial utilization of biological resources be required to comply with benefit-sharing obligations?

Decision: The Uttarakhand High Court upheld the relevant benefit-sharing framework against the challenge, recognizing the statutory basis for requiring benefit-sharing in the circumstances before it.

Relevance to blue biotechnology:

A company commercially exploiting Indian marine microorganisms, algae, or biochemical derivatives may need to assess statutory access and benefit-sharing obligations independently of its patent rights.

The case is particularly important in India because it connects commercial use of biological resources with public-law obligations and the interests of resource conservers.

Principle: Ownership or licensing of an invention does not automatically eliminate applicable biodiversity-law obligations.

For the current statutory position, India's National Biodiversity Authority publishes guidance on the amended Biological Diversity Act and access-and-benefit-sharing requirements.

National Biodiversity Authority+1

Case 7: Association for Molecular Pathology v. Myriad Genetics and the distinction between discovery and invention

This is worth emphasizing separately because it captures a recurring dispute in marine research.

A company may discover a previously unreported enzyme in a hydrothermal-vent microorganism. The legal analysis should distinguish among:

the naturally occurring enzyme;

a purified or isolated version;

a modified enzyme with materially different properties;

a synthetic analogue;

a manufacturing process using the enzyme; and

a particular industrial or therapeutic application.

These claims can have different outcomes. A naturally occurring substance may be unpatentable in a particular form, while a sufficiently inventive engineered variant or process may qualify. The applicable legal test must be applied to each claim rather than to the research project as a whole.

5. Indian statutory framework

India is particularly relevant to blue biotechnology because its marine biodiversity includes coastal ecosystems, coral reefs, mangroves, marine microorganisms, algae, and resources within its maritime zones.

A. Biological Diversity Act, 2002

The Biological Diversity Act, 2002, as amended, is central to access to Indian biological resources and benefit-sharing. The relevant provisions include:

The exact requirements depend on the person or entity involved, the origin and nature of the resource, the activity undertaken, and applicable exemptions. The National Biodiversity Authority's current guidance distinguishes among research, commercial utilization, applications for IP rights, and commercialization.

National Biodiversity Authority+1

The 2023 amendment is especially relevant because it revised statutory definitions and regulatory procedures, including provisions relating to derivatives and intellectual property rights. Consult the WIPO Lex legislation record and the National Biodiversity Authority for the applicable statutory text and guidance.

B. Patents Act, 1970

Several provisions of the Indian Patents Act, 1970, may be important in marine biotechnology disputes:

Section 2(1)(j): Defines an invention by reference to a new product or process involving an inventive step and capable of industrial application.

Section 3(c): Excludes the mere discovery of a scientific principle or formulation of an abstract theory, among other specified subject matter.

Section 3(j): Excludes plants and animals in whole or in part, other than microorganisms, including seeds, varieties and species, and essentially biological processes for production or propagation of plants and animals.

Section 10: Addresses the contents and disclosure requirements of patent specifications.

Section 25: Provides pre-grant and post-grant opposition mechanisms.

Section 64: Provides grounds for revocation of a patent.

Section 107A: Provides specified exceptions, including certain regulatory-use activities and acts connected with obtaining information required for regulatory submissions.

Section 3(j) should not be read as automatically excluding every invention involving marine life. The claim's subject matter and the statutory wording are decisive. For instance, a qualifying microbial invention may be treated differently from a claim to an animal species or an essentially biological process.

6. Common grounds for litigation

1. Patent infringement

A patent owner alleges that a competitor commercially uses a protected marine enzyme, engineered microorganism, formulation, or process without authorization.

Key question: Does the accused product or process fall within the valid claims of the patent?

2. Invalidity and prior art

A competitor argues that the claimed invention was previously disclosed in a scientific publication, an earlier patent, a database, or publicly available research.

Key question: Was the invention novel and inventive at the legally relevant date?

3. Unlawful access to genetic resources

A researcher or company is accused of collecting or utilizing marine biological material without satisfying applicable access requirements.

Key question: Which access-and-benefit-sharing regime applies to the sample, and were its requirements met?

4. Breach of research agreements

A university, research institute, or commercial partner alleges that another party improperly used jointly developed technology, unpublished data, or confidential biological samples.

Key question: What do the collaboration, material-transfer, licensing, and confidentiality agreements actually provide?

5. Inventorship and ownership disputes

Scientists, employers, universities, funders, and commercial sponsors disagree about entitlement to a patent.

Key question: Who qualifies as an inventor, and who owns the resulting rights under applicable law and contractual arrangements?

7. Illustrative hypothetical dispute

Consider an Indian marine biotechnology company that discovers a microorganism in Indian coastal waters. It develops a modified enzyme for industrial waste treatment and applies for a patent. A foreign competitor subsequently launches a similar enzyme.

Three separate legal disputes may arise.

Patent dispute: The Indian company must establish that its patent is valid and that the competitor's product falls within its claims. The competitor may challenge novelty, inventive step, disclosure, or the scope of the patent.

Biodiversity compliance dispute: The company must establish whether its collection, research, IP application, and commercialization complied with applicable provisions of the Biological Diversity Act and relevant regulations. A patent grant does not, by itself, resolve those questions.

Contractual dispute: If a university or overseas laboratory supplied the microorganism, the parties may disagree over inventorship, licensing rights, confidentiality, or contractual benefit-sharing.

The three disputes are related but legally distinct. Winning an infringement action would not automatically prove compliance with biodiversity legislation, just as a regulatory approval would not establish patent validity.

8. Remedies and dispute-resolution mechanisms

Depending on the jurisdiction and legal basis of the claim, available mechanisms may include:

Patent infringement proceedings: Injunctions, damages, or an account of profits where legally available.

Patent opposition or revocation: Challenges to the validity of a patent on statutory grounds.

Regulatory proceedings: Review by the competent biodiversity authority, including access or benefit-sharing determinations.

Contractual remedies: Arbitration, damages, termination, or other relief permitted by the agreement and applicable law.

Confidentiality remedies: Relief for misappropriation of trade secrets or breach of confidence.

International dispute resolution: Appropriate treaty mechanisms, arbitration, or domestic litigation where jurisdiction and consent permit.

A sound dispute strategy should identify the legal basis for each claim rather than treating patent rights, biodiversity compliance, and contractual obligations as interchangeable.

9. Practical compliance and prevention

For a marine biotechnology research project, a defensible compliance process should include:

Document the resource's origin. Record the collection location, date, organism, sample identifiers, and chain of custody.

Check access permissions. Determine whether collection permits, marine research approvals, biodiversity clearances, or other authorizations are required.

Review benefit-sharing terms. Establish applicable obligations before commercial development or transfer of the material.

Protect confidential information. Use material-transfer agreements, confidentiality clauses, and access controls for research data.

Assess patentability early. Conduct prior-art searches and distinguish naturally occurring material from genuinely inventive modifications or processes.

Clarify ownership. Use written agreements to allocate IP rights among researchers, institutions, sponsors, and collaborators.

Maintain evidence. Preserve laboratory notebooks, sequence records, invention disclosures, permits, contracts, and patent-filing documents.

For resources obtained from areas beyond national jurisdiction, the legal analysis must also account for the applicable international regime and any relevant implementing measures.

10. Conclusion

Blue biotechnology intellectual property disputes sit at the intersection of patent law, marine-resource governance, biodiversity conservation, commercial contracts, and international law.

The principal lessons from the case law are that biological discoveries are not automatically patentable, engineered biological inventions may qualify for protection, and patent ownership does not necessarily eliminate independent regulatory or benefit-sharing obligations.

In India, the interaction between the Patents Act, 1970, and the Biological Diversity Act, 2002, as amended, is particularly important. The outcome of a dispute depends on the invention's precise claims, the origin of the marine resource, the parties' legal status, the relevant permissions, and the governing agreements.

For academic or legal research, the next useful step is to develop a case-law matrix comparing Indian decisions with US patent precedents, with separate columns for facts, legal issues, holdings, statutory provisions, and relevance to marine biotechnology.